Final overall survival (OS) analysis of PROfound: Olaparib vs physician's choice of enzalutamide or abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations

Author
Gresty, C.
Hussain, M.
Olmos, D.
Thiery-Vuillemin, A.
Twardowski, P.
Roubaud, G.
ÖZGÜROĞLU, Mustafa
Kang, J.
Burgents, J.
Corcoran, C.
Adelman, C. A.
de Bono, J. S.
Mateo, J.
Fizazi, K.
Saad, F.
Shore, N.
Sandhu, S.
Chi, K. N.
Sartor, O.
Agarwal, N.
Metadata
Show full item record
URI
http://hdl.handle.net/20.500.12627/3570
https://doi.org/10.1016/j.annonc.2020.08.870
Collections